TriPath Imaging CEO Scheduled to Present at Deutsche Banc Alex. Brown's Health Care Conference

Apr 30, 2001, 01:00 ET from TriPath Imaging, Inc.

    BURLINGTON, N.C., April 30 /PRNewswire/ --
     TriPath Imaging, Inc. (Nasdaq:   TPTH) ("TriPath Imaging" or "the Company")
 today announced that Paul R. Sohmer, M.D., its Chairman, President and Chief
 Executive Officer, is scheduled to speak at the Deutsche Banc Alex. Brown's
 Health Care Conference in Baltimore, MD on Tuesday, May 8, at 4:30 p.m.(EDT).
     TriPath Imaging develops, manufactures and markets products to improve
 cancer screening.  Improved slide preparation technology is delivered through
 the AutoCyte PREP System(TM), a proprietary automated thin-layer cytology
 sample preparation system that produces specimen slides with a homogeneous,
 thin-layer of cervical cells, and is one of only two sample preparation
 systems approved by the FDA as a replacement for the conventional Pap smear.
 TriPath delivers visual intelligence technology to increase accuracy and
 productivity in medical testing through the AutoPap(R) Primary Screening
 System, which utilizes proprietary technology to distinguish between normal
 Pap smears and those that have the highest likelihood of abnormality.  In
 May 1998, AutoPap was approved by the U.S. Food and Drug Administration as the
 first and only fully automated device for primary screening of Pap smear
 slides.
     Forward-looking statements in this release are made pursuant to the safe
 harbor provisions of the Private Securities Litigation Reform Act of 1995.
 Investors are cautioned that statements in this press release which are not
 strictly historical statements constitute forward-looking statements which
 involve risks and uncertainties including, without limitation, risks
 associated with uncertainties regarding FDA approval, uncertainties regarding
 market acceptance and additional cost, risks associated with technological
 change, the Company's history of operating losses and the uncertainty of
 future profitability, dependence on a limited number of products, dependence
 on third-party reimbursement, limited marketing and sales experience, limited
 number of customers and lengthy sales cycle, risks of adverse changes in
 general economic conditions, and in the healthcare industry specific risks
 associated with competition and competitive pricing pressures, and other risks
 detailed in the Company's filings with the Securities and Exchange Commission.
 
     Contact:  Dr. Paul R. Sohmer, President & Chief Executive Officer, James
 D. Everhart, Director of Finance and Treasurer, or Kathryn E. Johnson, Manager
 of Corporate Communications and Investor Relations, TriPath Imaging, Inc.,
 (336) 222-9707
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X76077733
 
 

SOURCE TriPath Imaging, Inc.
    BURLINGTON, N.C., April 30 /PRNewswire/ --
     TriPath Imaging, Inc. (Nasdaq:   TPTH) ("TriPath Imaging" or "the Company")
 today announced that Paul R. Sohmer, M.D., its Chairman, President and Chief
 Executive Officer, is scheduled to speak at the Deutsche Banc Alex. Brown's
 Health Care Conference in Baltimore, MD on Tuesday, May 8, at 4:30 p.m.(EDT).
     TriPath Imaging develops, manufactures and markets products to improve
 cancer screening.  Improved slide preparation technology is delivered through
 the AutoCyte PREP System(TM), a proprietary automated thin-layer cytology
 sample preparation system that produces specimen slides with a homogeneous,
 thin-layer of cervical cells, and is one of only two sample preparation
 systems approved by the FDA as a replacement for the conventional Pap smear.
 TriPath delivers visual intelligence technology to increase accuracy and
 productivity in medical testing through the AutoPap(R) Primary Screening
 System, which utilizes proprietary technology to distinguish between normal
 Pap smears and those that have the highest likelihood of abnormality.  In
 May 1998, AutoPap was approved by the U.S. Food and Drug Administration as the
 first and only fully automated device for primary screening of Pap smear
 slides.
     Forward-looking statements in this release are made pursuant to the safe
 harbor provisions of the Private Securities Litigation Reform Act of 1995.
 Investors are cautioned that statements in this press release which are not
 strictly historical statements constitute forward-looking statements which
 involve risks and uncertainties including, without limitation, risks
 associated with uncertainties regarding FDA approval, uncertainties regarding
 market acceptance and additional cost, risks associated with technological
 change, the Company's history of operating losses and the uncertainty of
 future profitability, dependence on a limited number of products, dependence
 on third-party reimbursement, limited marketing and sales experience, limited
 number of customers and lengthy sales cycle, risks of adverse changes in
 general economic conditions, and in the healthcare industry specific risks
 associated with competition and competitive pricing pressures, and other risks
 detailed in the Company's filings with the Securities and Exchange Commission.
 
     Contact:  Dr. Paul R. Sohmer, President & Chief Executive Officer, James
 D. Everhart, Director of Finance and Treasurer, or Kathryn E. Johnson, Manager
 of Corporate Communications and Investor Relations, TriPath Imaging, Inc.,
 (336) 222-9707
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X76077733
 
 SOURCE  TriPath Imaging, Inc.

RELATED LINKS

http://www.autocyte.com